Boston Scientific (NYSE:BSX) Stock Gets Price Target Reduction from Sanford C. Bernstein

Boston Scientific (NYSE:BSX) had its target price trimmed by Sanford C. Bernstein from $54.00 to $49.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the medical equipment provider’s stock.

A number of other equities research analysts also recently weighed in on the stock. Wells Fargo & Company decreased their price target on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating on the stock in a research note on Thursday. Royal Bank Of Canada dropped their price objective on shares of Boston Scientific from $70.00 to $52.00 and set an “outperform” rating for the company in a research note on Thursday. Stifel Nicolaus dropped their price objective on shares of Boston Scientific from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, October 26th. Needham & Company LLC reduced their price objective on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Rothschild & Co Redburn decreased their target price on shares of Boston Scientific from $106.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $41.93 on Thursday. Boston Scientific has a 1-year low of $39.57 and a 1-year high of $105.65. The firm has a market capitalization of $60.77 billion, a PE ratio of 17.77, a PEG ratio of 1.03 and a beta of 0.58. The business’s 50 day moving average is $44.78 and its 200-day moving average is $56.88. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.73. The business had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. Boston Scientific’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.75 earnings per share. Sell-side analysts predict that Boston Scientific will post 3.17 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger acquired 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 189,522 shares of company stock worth $9,157,810. 0.34% of the stock is owned by insiders.

Institutional Investors Weigh In On Boston Scientific

Large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Boston Scientific during the second quarter worth approximately $5,534,781,000. Primecap Management Co. CA bought a new position in shares of Boston Scientific in the second quarter valued at approximately $2,156,233,000. Jupiter Topco LLC bought a new position in shares of Boston Scientific in the second quarter valued at approximately $803,357,000. Bank of America Corp DE bought a new position in shares of Boston Scientific in the second quarter valued at approximately $556,026,000. Finally, Legal & General Group Plc acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $431,890,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.